Results 91 to 100 of about 24,724 (196)

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma

BMC Cancer, 2018
Background Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the ...
Timothy Budden, Andre van der Westhuizen, Nikola A. Bowden   +2 more
doaj   +1 more source

HERVs, transposons and human diseases : part II [PDF]

, 2013
Part 1 and part 3 of the article can be found through this link : https://www.um.edu.mt/library/oar//handle/123456789/12961 https://www.um.edu.mt/library/oar//handle/123456789/13132Part 2 of the article.
Baldacchino, Sandra, Grech, Alfred
core  

A semantic web framework to integrate cancer omics data with biological knowledge [PDF]

, 2012
BACKGROUND: The RDF triple provides a simple linguistic means of describing limitless types of information. Triples can be flexibly combined into a unified data source we call a semantic model.
James P McCusker, Kei-Hoi Cheung, Matthew E Holford, Michael Krauthammer   +3 more
core   +1 more source

Physicochemical Stability of Reconstituted Decitabine (Dacogen®) Solutions and Ready-to-Administer Infusion Bags when Stored Refrigerated or Frozen

Pharmaceutical Technology in Hospital Pharmacy, 2017
Profound knowledge about the physicochemical stability is necessary in order to determine the “beyond-use-dates” of ready-to-administer preparations after reconstitution and dilution.
Kim Sun Hee, Heeb Rita Marina, Krämer Irene   +2 more
doaj   +1 more source

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Haematologica, 2012
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting.
Michael Lübbert, Björn H. Rüter, Rainer Claus, Claudia Schmoor, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Konstanze Döhner, Anne Hagemeijer, Pierre W. Wijermans, Hartmut Döhner   +18 more
doaj   +1 more source

New lipid nanocapsules for decitabine encapsulation [PDF]

, 2016
Introduction: Currently decitabine, an antimetabolite agent is approved for acute myeloid leukemia in old patients and is administered via intra-venous (IV) route.
E. Roger, F. Lagarce, N. Lautram, T. Briot   +3 more
core  

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer [PDF]

, 2014
PURPOSE: To investigate SGI-110 as a "chemosensitizer" in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer.
Azab, Mohammad, Choy, Gavin, Fang, Fang, Lyons, John, Matei, Daniela, Miller, David F. B., Munck, Joanne, Nephew, Kenneth P., Pawelczak, Katherine S., Pilrose, Jay, Tang, Jessica, Taverna, Pietro, Turchi, John J., VanderVere-Carozza, Pamela, Wagner, Michael, Wang, Yinu   +15 more
core   +1 more source

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Nature Communications, 2019
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a ...
Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl   +23 more
doaj   +1 more source

Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome

BIO Web of Conferences, 2017
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine ...
Fan Zhenwei, Wang Xuan, Zhao Chunshan, Wang Wei, Yu Tingting   +4 more
doaj   +1 more source

Decitabine and trichostatin A : a synergistic combination in ALL [PDF]

, 2009
Dissertação de mestrado integrado em Medicina, apresentado á Faculdade de Medicina da Universidade de CoimbraInvestigações recentes demonstraram que a regulação epigenética da expressão génica envolve a metilação regiões CpG, assim como a desacetilação ...
Costa, Carlos
core